(Q44244537)

1 December 2017

title

Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women (English)

1 reference

1 December 2017

LeRoy E Rabbani

1

1 reference

1 December 2017

Nicole A Seminario

2

1 reference

1 December 2017

Robert R Sciacca

3

1 reference

1 December 2017

Hong Jun Chen

4

1 reference

1 December 2017

Elsa-Grace V Giardina

5

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Journal of the American College of Cardiology

1 December 2017

published in

1 reference

1 December 2017

volume

40

1 reference

1 December 2017

issue

11

1 reference

1 December 2017

page(s)

1991-1999

1 reference

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

von Willebrand factor: a marker of endothelial damage?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Endothelial dysfunction and pathogenesis of diabetic angiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Plasma tissue plasminogen activator levels in patients with coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Hemostatic function and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Localized reduction of atherosclerosis in von Willebrand factor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Effects of hormone replacement therapy on hemostatic cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Hormone replacement therapy, inflammation, and hemostasis in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Hormone replacement therapy and increased plasma concentration of C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

The acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Cytokine-induced alteration of platelet and hemostatic function

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Effect of estrogen on the size of low-density lipoprotein particles in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

Compliance with hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2902565-2

7 January 2021

10.1016/S0735-1097(02)02565-2

Identifiers

DOI

1 reference

1 December 2017

1 reference